Literature DB >> 8103042

Ecstasy abuse in Ireland.

M T Cregg1, J A Tracey.   

Abstract

Since the late 1970s, ecstasy (MDMA) has enjoyed increasing popularity as a recreational drug. We report a dramatic increase in reports of ecstasy ingestion to the National Poisons Information Centre from zero in January 1991 to thirty seven in June 1992. We have analysed these thirty seven cases retrospectively for age and sex distribution, clinical details and outcome. The patients involved were predominantly male (80%) and aged 10-30 years, the highest incidence being in the 16-25 year old age group. Thirty two (86%) patients were symptomatic. Symptoms in most cases were relatively mild. One death was reported due to congestive heart failure. The symptoms most frequently reported include dilated pupils, agitation, excitement, hallucinations, tachycardia, palpitations, CNS depression, incontinence and psychiatric symptoms.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8103042

Source DB:  PubMed          Journal:  Ir Med J        ISSN: 0332-3102


  4 in total

Review 1.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

2.  Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths.

Authors:  Li-Tzy Wu; William E Schlenger; Deborah M Galvin
Journal:  Drug Alcohol Depend       Date:  2006-02-17       Impact factor: 4.492

3.  Hallucinogen-related disorders in a national sample of adolescents: the influence of ecstasy/MDMA use.

Authors:  Li-Tzy Wu; Christopher L Ringwalt; Roger D Weiss; Dan G Blazer
Journal:  Drug Alcohol Depend       Date:  2009-06-04       Impact factor: 4.492

4.  Hallucinogen use disorders among adult users of MDMA and other hallucinogens.

Authors:  Li-Tzy Wu; Christopher L Ringwalt; Paolo Mannelli; Ashwin A Patkar
Journal:  Am J Addict       Date:  2008 Sep-Oct
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.